The antibiotic invention, Exblifeb incorporates Enmetazobactam, the first completely invented-in-India beta lactamase inhibitor. It was designed to address the global challenge of anti-microbial resistance (AMR).

As a viable solution in fight against AMR, Exblifeb indicates efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia and bacteremia caused by Extended Spectrum Beta-lactamase producing pathogens.

During clinical trials, 'Exblifeb' exhibited superior performance compared to the current go-to drug, Piperacillin + Tazobactam. It is positioned as a potent, cost-effective, and Carbapenem-sparing therapy, offering a viable solution in the fight against rising AMR, stated the pharma company.

Enmetazobactam was invented in India by Orchid and then out-licensed to Allecra Therapeutics for further development.

Manish Dhanuka, managing director said, “With the potential to save thousands of lives globally, this approval by EMA is a testament to Indian ingenuity. It is also a matter of great pride that as the pharmacy of the world, India has now developed a new drug for the first time.”

Orchid Pharma is one of the leading pharmaceutical companies in India head quartered in Chennai and involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals with exports spanning over 40 countries.

The company reported a consolidated net profit of Rs 19.80 crore in Q2 FY24 as against a net loss of Rs 5.39 crore posted in Q2 FY23. Revenue from operations increased 20.27% YoY to Rs 198.76 crore during the quarter ended 30 September 2023.

Shares of Orchid Pharma were freezed at its 52-week high of Rs 859.40 in intraday session today.